Xoma Restructures, Focuses On Diabetes Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Antibody developer reluctantly releases HCD122 to Novartis for cash now and royalties later.
You may also be interested in...
Troubled Biotechs: Akesis, Metabasis, Xoma, Neurobiological Technologies
California nightmare? San Diego-based Akesis files for Chapter 7 bankruptcy while three other Golden State biotechs try to deal with their own financial maladies.
Troubled Biotechs: Akesis, Metabasis, Xoma, Neurobiological Technologies
California nightmare? San Diego-based Akesis files for Chapter 7 bankruptcy while three other Golden State biotechs try to deal with their own financial maladies.
Will JUPITER Change Statin Use?
Positive results from AstraZeneca’s outcomes trial of Crestor have all eyes on whether statin utilization will undergo a paradigm shift.